Pharvaris Director Exercises Options, Sells 800 Shares

Q: How did PHVS director Schikan's stock options vest?

25% of the option vested on February 5, 2022, with the remaining shares vesting in 1/48 monthly installments thereafter.

The stock-option transaction line reports 34,200 shares following the exercise, with the options expiring February 5, 2031.

Available on EDGAR 09/24/2026 - 10:44 AM EDT Accepted by SEC EDGAR 09/24/2026 - 10:43 AM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Pharvaris N.V. director Johannes Gerardus Christiaan Petrus Schikan exercised 800 stock options on September 22, 2026, at a $20 exercise price, acquiring 800 common shares and selling 800 shares in a cashless exercise transaction. The sale price was a weighted average $36.19 per share, with transaction prices from $36.15 to $36.23. The stock-option line reports 34,200 shares following the transaction; no Rule 10b5-1 plan is reported.

Insider Trade Summary

Exercise and Sale: 800 shares ($13K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Schikan Johannes Gerardus Christiaan Petrus

Role Director

Sold 800 shs ($29K)

Approx. gross sale proceeds $29K

Approx. exercise cost $16K

Approx. pre-tax spread $13K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) ^F2	800	$0.00	$0.00
Exercise	Common Stock	800	$20.00	$16K
Sale	Common Stock ^F1	800	$36.19	$29K

Holdings After Transaction: Stock Option (Right to Buy) — 34,200 options (Direct); Common Stock — 115,167 shares (Direct)

Footnotes (2)

F1. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $36.15 to $36.23. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F2. 25% of the option vested on February 5, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.

Key Figures

Stock options exercised: 800 shares Exercise price: $20 per share Common shares acquired: 800 shares +4 more

7 metrics

Stock options exercised 800 shares September 22, 2026

Exercise price $20 per share Options exercised on September 22, 2026

Common shares acquired 800 shares September 22, 2026

Common shares sold 800 shares Cashless exercise transaction on September 22, 2026

Weighted average sale price $36.19 per share Shares sold on September 22, 2026

Sale price range $36.15 to $36.23 per share Transactions on September 22, 2026

Shares following stock-option transaction 34,200 shares Reported following the September 22, 2026 transaction

Key Terms

cashless exercise transaction, weighted average sale price, 1/48 monthly installments, Stock Option (Right to Buy)

4 terms

cashless exercise transaction financial

"shares sold in connection with the exercise of stock options in a cashless exercise transaction"

weighted average sale price financial

"reported price represents a weighted average sale price for shares sold in multiple transactions"

1/48 monthly installments technical

"remaining shares vesting in 1/48 monthly installments thereafter"

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PHVS shares did director Schikan sell, and at what price?

On September 22, 2026, Pharvaris director Johannes Gerardus Christiaan Petrus Schikan sold 800 common shares in a cashless exercise transaction at a weighted average sale price of $36.19 per share. The reported sale prices ranged from $36.15 to $36.23 per share.

How did PHVS director Schikan's stock options vest?

25% of the option vested on February 5, 2022, with the remaining shares vesting in 1/48 monthly installments thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schikan Johannes Gerardus Christiaan Petrus

(Last)

(First)

(Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON

MASSACHUSETTS

02421

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/22/2026		M		800	A	$20	115,967	D
Common Stock	09/22/2026		S		800	D	$36.19⁽¹⁾	115,167	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$20	09/22/2026		M			800	⁽²⁾	02/05/2031	Common Stock	800	$0	34,200	D

Explanation of Responses:

1. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $36.15 to $36.23. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

2. 25% of the option vested on February 5, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.

	/s/ Marnus Nel, Attorney-in-Fact for Johannes Schikan	09/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR